特利加压素+人血白蛋白治疗肝硬化顽固性腹水患者的效果  

Effect of Terlipressin Plus Human Serum Albumin on Refractory Ascites due to Cirrhosis

作　　者：万咏杰 WAN Yongjie(Department of Third Liver Disease,Dalian Sixth People's Hospital,Dalia 116001,China)

机构地区：[1]大连市第六人民医院肝病三科,辽宁大连116001

出　　处：《中国医药指南》2021年第8期77-78,共2页Guide of China Medicine

摘　　要：目的探讨特利加压素+人血白蛋白治疗肝硬化顽固性腹水患者的效果。方法选取本院2017年3月至2019年2月收治的280例肝硬化顽固性腹水患者,随机分为研究组(140例)和对照组(140例)。对照组在常规治疗基础上进行人血白蛋白治疗,研究组在对照组基础上加特利加压素治疗。观察两组患者的治疗效果。结果治疗后,研究组患者的腹围、心率、24 h尿量、凝血酶原时间、治疗总有效率、血白蛋白、肌酐和尿钠均优于对照组(P<0.05)。两组不良反应比较无差异(P>0.05)。结论肝硬化顽固性腹水患者应用特利加压素联合人血白蛋白治疗的效果确切,有助于改善患者的临床症状和肝功能,用药安全性较高。Objective To study the effect of terlipressin plus human serum albumin in the treatment of refractory ascites due to cirrhosis.Methods A total of 280 patients with refractory ascites due to cirrhosis admitted to our hospital from March 2017 to February 2019 were randomly divided into study group(140 cases)and control group(140 cases).The control group was treated with human albumin on the basis of routine treatment,while the study group was treated with terlipressin on the basis of the control group.The therapeutic effect of the two groups was observed.Results After treatment,the abdominal circumference,heart rate,24-hour urine output,prothrombin time,total effective rate of treatment,serum albumin,creatinine and urine sodium of the study group were better than those of the control group(P<0.05).There was no difference in adverse reactions between the two groups(P>0.05).Conclusion The effect of terlipressin combined with human albumin treatment on patients with cirrhosis and refractory ascites is definite,which helps to improve the clinical symptoms and liver function of the patients,and the medication is safer.

关 键 词：肝硬化 顽固性腹水 特利加压素 人血白蛋白 生化指标 

分 类 号：R657.31[医药卫生—外科学]